Press Release: LUX-Head & Neck 1 & 2 Trial Initiation
Press Release BIBF 1120* in mCRC
Press release Lux Breast Cancer Trial August 2011
Press release New Lux-Lung 1 data December 2010
Afatinib lung cancer trial results
Press Release LUX-Breast 1 Initiation September 2010
BIBW 2992 cancer treatment data presented at ASCO
Press release LUME-Ovar 1 December 2009
Boehringer Ingelheim to commence Lux Lung 3 study investigating the role of BIBW 2992* as first-line treatment for non-small cell lung cancer (NSCLC) patients with EGFR mutations
Boehringer Ingelheim and DxS sign agreement for a companion diagnostic test to identify EGFR mutations in patients with lung cancer
Boehringer Ingelheim to present new data on two lead oncology compounds at ASCO 2009
Press release LUME-Lung 1+2 November 2008
Clinical trials data suggests promising overall survival and progression-free survival in patients with NSCLC using BIBF 1120*
Press release Lux phase 3 BIBW 2992 (afatinib)
Boehringer Ingelheim accesses field of oncology
Source for healthcare professionals: www.inoncology.com* BIBF 1120, BIBW 2992 and BI 6727 are investigational compounds. Their safety and efficacy have not yet been fully established.